secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001493152-22-013520
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Q1 net loss $10.9M; Phase 2b PAH trial topline data expected Q4 2023/Q1 2024
--------------------------------------------------------------------------------

- Net loss Q1 2022 $10.9M vs $2.8M in 2021; R&D up to $7.3M, G&A up to $3.8M.
- Cash and investments $161.1M; cash runway into second half of 2025.
- Site initiation delays push Phase 2b topline data from IMPAHCT trial to Q4 2023 or Q1 2024.
- Hired Marco Verwijs as SVP CMC and Susan Fischer as SVP Development Operations.
- Expanded IP portfolio with new U.S. patent and allowances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000149315222013520/0001493152-22-013520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000149315222013520/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-013520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer